Riyadh Biotech Summit Closes With $1.3B in Deals and Programs
The three-day meeting drew 15,000 visitors from 57 countries and produced agreements across gene therapy, vaccines, clinical trials and genomics.
Tariq Benali Tariq Benali covers business and corporate news across the UAE and MENA for Anecdoted, tracking the deals, leadership moves and regulatory shifts behind the region's companies. tariq@anecdoted.com
The fourth Riyadh Global Medical Biotechnology Summit wrapped on September 16 after producing more than 40 agreements, initiatives and announcements with a combined value above $1.3 billion (SAR 5 billion). The event has become the kingdom's main stage for converting its National Biotechnology Strategy into research, investment, manufacturing and talent programs.
Attendance and reach
Organizers counted more than 15,000 visitors from over 57 countries, more than 200 speakers and over 180 strategic meetings across the three days.
Bandar Alknawy, chief executive of the Ministry of National Guard Health Affairs, president of King Saud bin Abdulaziz University for Health Sciences and KAIMRC, and chairman of the summit, said the most significant result was the shift from setting ambitions to showing implementation. The platform has been built since 2021, he said, and the strategy's launch in 2024, alongside the previous edition of the summit, raised the bar for what the event had to deliver. Two years on, milestones are moving off paper.
Where the agreements landed
Announcements were grouped under four pillars: government strategy and regulation, investment and funding, research and development readiness, and capability building.
- KAIMRC and Thermo Fisher Scientific set up a Center of Excellence for Genomics, Proteomics and Biobanking.
- An agreement with Novo Nordisk is intended to strengthen clinical-trial capabilities, including earlier-phase trials.
- Research collaborations involve Olink, Tiziana Life Sciences and Japan's Chiyoda Corporation.
On gene therapy, the KAIMRC and AstraZeneca localization program has moved from program approval to established preclinical models, with hit-finding completed. The summit program included a session on that gene therapy localization journey. Saudi-led research was placed alongside international scientific work rather than positioning local institutions only as participants, Alknawy said.
Manufacturing and funding
Vaccine Industrial Company said its $133.1 million (SAR 500 million) human vaccine manufacturing facility, covering 42,000 square meters, is 85 percent complete and is planned to localize up to 80 percent of the kingdom's essential vaccine needs.
Five investment funds signaled willingness to commit more than $120 million through the Life Sciences Innovation Forum, where 23 biotechnology companies from eight countries pitched their businesses.
Execution as the next test
Alknawy attributed the level of engagement to a clear national framework for biotechnology, growing international interest in the kingdom's opportunities in clinical trials, biosimilars, vaccines and biologics manufacturing, and the summit's ability to convene policymakers, regulators, researchers, investors, manufacturers and companies in one place.
For the next phase, he said execution comes first. Each commitment has to move from signature to defined milestones, accountable partners and measurable outcomes, and the agreements sit at different stages across infrastructure, research capabilities, clinical trials, genomics, precision medicine and specialized talent.
He added that the benchmark for the summit will be its effect on patients rather than the headline value of its deals: whether the partnerships lead to earlier diagnosis, more effective treatments, wider access to advanced therapies and a better quality of life for patients and their families.
